Inhibitors of multidrug resistance

Current Opinion in Oncology

Volumn 9, Issue 6, 1997, Pages 543-548

  Sonneveld, Pieter ^a   Wiemer, Erik ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA (4 ACETYLPHENYL) 17BETA HYDROXY 17ALPHA (1 PROPYNYL)ESTRA 4,9 DIEN 3 ONE; ACRIDINE DERIVATIVE; CALCIUM ANTAGONIST; COMPLEMENTARY DNA; CYCLOSPORIN A; CYTOKINE; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; MIDOSTAURIN; MONOCLONAL ANTIBODY; PROTEIN KINASE C; RIBOZYME; TUNICAMYCIN; VALSPODAR; VERAPAMIL; VERLUKAST;

CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG TRANSPORT; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW;

EID: 0030825823     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199711000-00009     Document Type: Review

References (62)

1. Nooter K, Stoter G: Molecular mechanisms of multidrug resistance in cancer chemotherapy. Path Res Prac 1996, 192:768-780.
2. Loe DW, Deeley RG, Cole SPW: Biology of the multidrug-resistance in tumour cells. Eur J Cancer 1996, 32A:945-957.
3. Izquierdo MA, Scheffer GL, Flens MJ, Schroeijers AB, van der Valk P, Scheper RJ: Major vault protein LRP-related multidrug resistance. Eur J Cancer 1996, 32A:979-984.
4. Nitiss LJ, Beck WT: Anti-topoisomerase drug action and resistance. Eur J Cancer 1996, 32A:958-966.
5. Hanna M, Gros P: Cloning and structure: function analysis of the mouse mdr1 gene family. In Multidrug resistance in cancer cells. Edited by Gupta S, Tsuruo T. John Wiley & Sons, Chichester; 1996:5-28.
6. Germann UA: Molecular analysis of p-glycoprotein. Eur J Cancer 1996, 32A:927-944.
7. Tsuruo T, Tsukagoshi S, Sakurai Y: Overcoming vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1982, 41:1967-1972.
8. Ford JM: Experimental reversal of p-glycoprotein-mediated multidrug resistance by pharmacological chemosensitizers. Eur J Cancer 1996, 32A:991-1001.
9. Berg S, Tolcher A, O'Shaugnessy JA: Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. J Clin Oncol 1995, 13:2039-2042.
10. Boer R, Haas M, Schodl A: Influence of dexniguldipine-HCl on rhodamine-123 accumulation in a multidrug-resistant leukaemia cell line: comparison with other chemosensitisers. Eur J Cancer 1994, 30A:1117-1123.
11. Greenberger L, Collins KI, Annable T, Boni JP, May MK, Lai FM, Kramer R, Citeralla RV, Hallett WH, Powell D: Alpha-(3,4-dimethyoxyphenyl)-3,4-dihydro-6,7dimethoxy-alpha-[(4-methylphenyl) thio]-2(1H)-isoquinolineheptanenitrile (CL 329,753): a novel chemosensitizing agent for p-glycoprotein-mediated resistance with improved biological properties compared with verapamil and cyclosporine A. Oncol Res 1996, 8:207-218.
12. Fisher GA, Lum BL, Hausdorff J, Sikic BI: Pharmacological considerations in the modulation of multidrug resistance. Eur J Cancer 1996, 32A:1082-1088. A comprehensive overview of the multiple pharmacokinetic effects that occur when effective MDR reversal agents are combined with cytotoxic agents.
13. Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, Loor F: In vivo circumvention of p-glycoprotein-mediated multidrug resistance by SDZ PSC 833. Cancer Res 1991, 27:1639-1642.
14. Sonneveld P, Marie JP, Huisman C, Vekhoff A, Schoester M, Faussat AM, van Kapel J, Groenewegen A, Charnick S, Zittoun R, Löwenberg B: Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma: a phase I study. Leukemia 1996, 10:1741-1750. This report of a reversal study with PSC833 shows the various aspects of p-glycoprotein reversal, pharmacokinetics, toxicity, and treatment results that are typical for clinical studies with reversal agents.
15. Vickers AEM, Meyer E, Dannecker R, Keller B, Tynes RE, Maurer G: Human liver cytochrome P4503A biotransformation of the cyclosporin derivative SDZ IMM 125. Am Soc Pharmacol Exp Ther 1995, 23:321-326.
16. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, van der Valk MA, Voordauw AC, van Tellingen O, Zijlmans JM, Fibbe WE, Borst P: Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) p-glycoproteins. Proc Natl Acad Sci U S A 1997, 94:4028-4033. Excellent paper demonstrating that p-glycoprotein is involved in transmembrane transport of drugs.
17. Tolomeo M, Gancitano RA, Musso M, Porretto F, Perricone R, Abbadessa V, Cajozzo A: Comparative activity of idarubicin and idarubicinol in combination with cyclosporin A in multidrug-resistant leukemia cells. Cancer Chemother Pharmacol 1996, 39:156-161.
18. Consoli U, Priebe W, Ling Y, Mahadevia R, Griffin M, Zhao S, Soler R, Andreeff M: The novel anthracycline annamycin is not affected by p-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines. Blood 1996, 88:633-644.
19. Lampidis TJ, Kolonias D, Podona T, Israel M, Safa AR, Lothstein L, Savaraj NN, Tapiero H, Priebe W: Circumvention of P-gp MDR as a function of anthracycline lipophilicity and charge. Biochemistry 1997, 36:2679-2685.
20. Ripamonti M, Capolongo L, Lelegaro G, Gornati C, Bargiotti A, Caruso M, Grandi M, Suarato A: Morpholinylanthracyclines: cytotoxicity and antitumor activity of differently modified derivatives. Invest New Drugs 1996, 14:139-146.
21. Uziely B, Jeffers S, Isacson R, Kutsch L, Wei-Tsao D, Yehoshua Z, Libson E, Muggia FM, Gabizon A: Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995, 13:1777-1785.
22. den Ouden D, van den Heuvel M, Schoester M, van Rens G, Sonneveld P: In vitro effect of GF120918, a novel reversal agent of multidrug resistance, on acute leukemia and multiple myeloma cells. Leukemia 1996, 10:1930-1936.
23. Dodic N, Dumaitre B, Daugan A, Pianetti P: Synthesis and activity against multidrug resistance in Chinese hamster cells of new acridone-4-carboxamides. J Med Chem 1995, 38:2418-2426.
24. Ciba P, Burghofer S, Richter E, Tell B, Moser A, Ecker G: Synthesis, pharmacologic activity, and structure-active relationships of a series of propafenone-related modulators of multidrug-resistance. J Med Chem 1995, 38:2789-2793.
25. Ford JM, Prozialeck WC, Hait WN: Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol Pharmacol 1989, 35:105-115.
26. Walker RJ, Lazzaro VA, Duggin GG, Hotvath JS, Tiller DJ: Cyclosporin A inhibits protein kinase C activity: a contributing mechanism in the development of nephrotoxicity? Biochem Biophys Res Commun 1989, 160:409-415.
27. Ichikawa M, Yoshimura A, Furukawa T, Sumizawa T, Nakazima Y, Akiyama S: Glycosylation of p-glycoprotein in a multidrug-resistant KB cell line, and in human tissues. Biochim Biophys Acta 1991, 1073:309-315.
28. Budworth J, Davies R, Malkhandi J, Gant T, Ferry DR, Gescher A: Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to p-glycoprotein in multidrug-resistant MCF-7/Adr cells. Br J Cancer 1996, 73:1063-1068.
29. List AF, Spier C, Greer J, Wolff S, Mutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W: Phase I/II trial of cyclosporine as a chemotherapy resistance modifier in acute leukemia. J Clin Oncol 1994, 11:1652-1660.
30. Wilson WH, Bates SE, Fojo A, Chabner BA: Modulation of multidrug resistance by dexverapamil in EPOCH-refractory lymphomas. J Cancer Res Clin Oncol 1995, 121(Suppl 3):25-29.
31. Kornblau SM, Estey E, Madden T, Tran HT, Zhao S, Consoli U, Snell V, Sanchez-Williams G, Kantarjian H, Keating M, Newman RA, Andreeff M: Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC 833 in relapsed or refractory acute myelogenous leukemia. J Clin Oncol 1997, 15:1796-1802.
32. Wilson WH, Jamis-Dow C, Bryant G: Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. J Clin Oncol 1995, 13:1985-1994.
33. Wilson WH, Bates SE, Fojo A: Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 1995, 13:1995-2004.
34. Motzer RJ, Lyn P, Fischer P: Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. J Clin Oncol 1995, 13:1958-1965.
35. Tolcher AW, Cowan KH, Solomon D, Ognibene F, Goldspiel B, Chang R, Noone H, Denicoff M, Barnes S, Gossard R, Fetsch A, Berg L, Venzon J, O'Shaugnessy JA: Phase I crossover study of paclitaxel with R-verapamil in patients with metastatic breast cancer. J Clin Oncol 1996, 14:1173-1184.
36. Mickisch GH, Noordzij MA, van der Gaast A, Gebreamlack P, Kohrmann KU, Mogler-Drautz E, Kupper H, Schröder FH: Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma. J Cancer Res Clin Oncol 1995, 121:11-16.
37. Boote D, Dennis I, Twentyman P, Osborne RJ, Laburte C, Hensel S, Smyth JF, Brampton MH, Bleehen NM: Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 1996, 14:610-618.
38. Hausdorff J, Fisher GA, Halsey J, Mallarino MC, Lum BL, Sikic BI: Doxorubicin, paclitaxel, and oral PSC 833, a modulator of multidrug resistance (MDR): a phase I trial (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1996, 15:A397.
39. Fracasso PM, Fisher GA, Wiehl JG, Collins H, Hausdorff J, Williams KM, Halsey J, Pearce TE, Sikic BI: Phase I trial of paclitaxel (Taxol) and SDZ PSC 833 in patients with solid tumors (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1995, 14:A1585.
40. Hausdorff J, Fisher GA, Halsey J, Collins HI, Lum BL, Brophy NA, Duran GE, Nix D, Pearce T, Sikic BI: A phase I trial of etoposide with the oral cyclosporin SDZ PSC 833, a modulator of multidrug resistance (MDR) [abstract]. Proc Annu Meet Am Soc Clin Oncol 1995, 14:A407.
41. Beck WT, Grogan TM, Willman C, Cordon-Cardo C, Parham DM, Kuttesch JF, Andreeff M, Bates SE, Berard CW, Boyett JM, Brophy NA, Broxterman HJ, Chan HS, Dalton WS, Dietel M, Fojo AT, Gascoyne RD, Head D, Houghton PJ, Srivastava DK, Lehnert M, Leith CP, Paietta E, Pavelic ZP, Weinstein R: Methods to detect p-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 1996, 56:3010-3020. This paper is a report from a workshop held to compare and standardize analytical assays for p-glycoprotein expression. It shows that the interlaboratory variability of assays and assay results is considerable, making interpretation of the results difficult. It accentuates the need for standard assays and definitions of results.
42. Dalton WS, Crowley JJ, Salmon SE, Grogan TM, Laufman LR, Weiss GR, Bonnet JD: A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma: a Southwest Oncology Group Study. Cancer 1995, 75:815-820.
43. Solary E, Witz B, Caillot D, Moreau P, Desablens B, Cahn JY, Sadoun A, Pignon B, Berthou C, Maloisel F, Guyotat D, Casassus P, Ifrah N, Lamy Y, Audhuy B, Colombat P, Harousseau JL: Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. Blood 1996, 88:1198-1205.
44. Lehne G, De Angelis P, Clausen OPF, Rugstad HE: Human hepatoma cells rich in p-glycoprotein are sensitive to aclarubicin and resistant to three other anthracyclines. Br J Cancer 1996, 74:1719-1729.
45. Ojima I, Slater JC, Kuduk SD, Takeuchi CS, Gimi RH, Sun CM, Park YH, Pera P, Veith JM, Bernacki RJ: Syntheses and structure-activity relationships of taxoids derived from 14 beta-hydroxy-10-deacetylbaccatin III. J Med Chem 1997, 40:267-278.
46. Leonce S, Perez V, Casabianca-Pignede MR, Anstett M, Bisagni E, Pierre A, Atassi G: In vitro cytotoxicity of S16020-2, a new olivacine derivative. Invest New Drugs 1996, 14:169-180.
47. Pannocchia A, Reveill S, Tamponi G, Giorgianni A, Todde R, Bosia A, Ghigo D: Reversal of doxorubicin resistance by the amiloride analogue EIPA in multidrug resistant human colon carcinoma cells. Cell Biochem Funct 1996, 14:11-18.
48. Hu Y-P, Jarillon S, Dubernet C, Couvreur P, Robert J: On the mechanism of action of doxorubicin encapsulation in nanospheres for the reversal of multidrug resistance. Cancer Chemother Pharmacol 1996, 37:556-560.
49. Fritzer M, Szekeres T, Szuts V, Jarayam HN, Goldenberg H: Cytotoxic effects of a doxorubicin-transferrin conjugate in multidrug-resistant KB cells. Biochem Pharmacol 1996, 51:489-493.
50. Goodfellow HR, Sardini A, Ruetz S, Callaghan R, Gros P, McNaughton PA, Higgins CF: Protein kinase C-mediated phosphorylation does note regulate drug transport by the human multidrug resistance p-glycoprotein. J Biol Chem 1996, 271:13668-13674. This paper shows unequivocally that phosphorylation has no role in modulating drug transport activity in human p-glycoprotein. All potential phosphorylation sites (eight serine and threonine residues) in the p-glycoprotein linker region were mutated so they could no longer be phosphorylated by protein kinase C. Drug transport rates were found to be unaffected when these p-glycoprotein mutants were expressed in yeast and mammalian cells. These observations are important because several p-glycoprotein reversal strategies are based on the assumption that protein kinase C-mediated phosphorylation regulates drug transport by p-glycoprotein. In the discussion section, the authors address the apparent contradictions between previous reports in the literature and their own data and postulate an alternative functional role for p-glycoprotein phosphorylation.
51. Bouffard DY, Ohkawa T, Kijima H, Irie A, Suzuki T, Curcio LD, Holm PS, Sassani A, Scanlon KJ: Oligonucleotide modulation of multidrug resistance. Eur J Cancer 1996, 32A: 1010-1018.
52. Stein U, Walther W, Shoemaker RH: Modulation of mdr1 expression by cytokines in human colon carcinoma cells: an approach for reversal of multidrug resistance. Br J Cancer 1996, 74:1384-1391.
53. O'Brien M, Paul S, Kruh G, Tew K: Modulators of glutathione and glutathione-S-transferase in multidrug resistance associated protein (MRP) overexpressing cells. Proc Am Assoc Cancer Res 1997, A2948, 441.
54. Leonessa F, Green G, Lippman J, Clarke R: The steroidal agent ZK 112993 inhibits the multidrug resistance (MDR) phenotype associated with the expression of the multidrug resistance protein (MRP). Proc Am Assoc Cancer Res 1997, A3968, 591.
55. Curtin N, Turner D: Reversal of drug-resistance by dipyridamole in multidrug resistance-associated protein (MRP)-overexpressing cells. Proc Am Assoc Cancer Res 1997, A3972, 591.
56. Nakamura T, Oka M, Narasaki F, Ikeda K, Fukuda M, Terashi K, Nakano R, Satoh S, Mizuta Y, Tsuruo T, Kohno S: A quinoline derivative, MS-209, overcomes multidrug resistance of human gastric cancer cells. Proc Am Assoc Cancer Res 1997, A3976, 592.
57. Sumizawa T, Chen ZS, Chuman Y, Seto K, Furukawa T, Haraguchi M, Tani A, Shudo N, Akiyama SI: Reversal of multidrug resistance-associated protein-mediated drug resistance by the pyridine analog PAK-104P. Mol Pharmacol 1997, 51:399-405.
58. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Steward AJ, Kurz EV, Duncan AM, Deeley RG: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992, 258:1650-1654.
59. Kool M, de Haas M, Paulusma C, Scheffer G, Scheper R, Oude Elferink R, Baas F, Borst P: Four homotogs of the multidrug resistance protein MRP1. Proc Am Assoc Cancer Res 1997, A2941, 440.
60. Scheffer GL, Wijngaard PLJ, Flens MJ, Izquierda MA, Slovak ML, Pinedo HM, Meijer CJLM, Clevers HC, Scheper RJ: The drug resistance-related protein LRP is the human major vault protein. Nature Medicine 1995, 1:578-582.
61. Kickhoefer VA, Vasu SK, Rome LH: Vaults are the answer, what is the question? Trends Cell Biol 1996, 6:174-178. Excellent overview of the state of affairs regarding the vault complex in various organisms. Although this evolutionary conserved organelle is abundantly present in eukaryotic cells, its precise functional role is still elusive. Included is a section discussing how vaults might be operational in multidrug resistance.
62. Izquierdo MA, Scheffer GL, Flens MJ, Shoemaker RH, Rome LH, Scheper RJ: Relationship of the LRP-human major vault protein to in vitro and clinical resistance to anticancer drugs. Cytotechnology 1996, 19:191-207.